Modulation of UL24 interactions with protein targets and uses thereof for inhibition of herpesvirus infection
View Patent ↗Methods and uses for the treatment of herpesvirus infection based on the inhibition of the interaction between herpesvirus UL24 and non-muscle myosin type IIa (NM2a) are described.
1. A method for determining whether an agent may be useful for inhibiting the interaction between herpesvirus UL24 and non-muscle myosin type IIa (NM2a), wherein said method comprises contacting the UL24 polypeptide of SEQ ID NO:2 and the NM2a polypeptide of SEQ ID NO:4 in the presence of said agent, and determining whether the interaction between said UL24 and NM2a polypeptides is inhibited in the presence of said agent, wherein inhibition of the interaction between said UL24 and NM2a polypeptides in the presence of said agent is indicative that said agent may be useful for inhibiting the interaction between UL24 and NM2a.
2. The method of claim 1 , wherein said UL24 polypeptide and/or said NM2a polypeptide are expressed in an isolated cell.
3. The method of claim 2 , wherein said isolated cell is an isolated cell transfected or transformed with (i) a nucleic acid encoding said UL24 polypeptide of SEQ ID NO:2; (ii) a nucleic acid encoding said NM2a polypeptide of SEQ ID NO:4; or (iii) both (i) and (ii).